SEC Form 4 · accession 0001930479-26-000003
Praxis Precision Medicines, Inc. · PRAX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jill DeSimone
Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 5:09 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001689548
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 24, 2026 | M | 8,566 | $44.25 | A | 10,903 | D | |
| Common Stock | Jun 24, 2026 | M | 3,034 | $147.30 | A | 13,937 | D | |
| Common Stock | Jun 24, 2026 | S | 10 | $301.44 | D | 13,927 | D | |
| Common StockF2 | Jun 24, 2026 | S | 120 | $303.127 | D | 13,807 | D | |
| Common StockF3 | Jun 24, 2026 | S | 320 | $305.31 | D | 13,487 | D | |
| Common StockF4 | Jun 24, 2026 | S | 683 | $306.767 | D | 12,804 | D | |
| Common StockF5 | Jun 24, 2026 | S | 1,240 | $308.243 | D | 11,564 | D | |
| Common StockF6 | Jun 24, 2026 | S | 999 | $309.383 | D | 10,565 | D | |
| Common StockF7 | Jun 24, 2026 | S | 1,750 | $310.889 | D | 8,815 | D | |
| Common StockF8 | Jun 24, 2026 | S | 2,854 | $311.914 | D | 5,961 | D | |
| Common StockF9 | Jun 24, 2026 | S | 1,004 | $312.83 | D | 4,957 | D | |
| Common StockF10 | Jun 24, 2026 | S | 504 | $313.663 | D | 4,453 | D | |
| Common StockF11 | Jun 24, 2026 | S | 1,279 | $314.901 | D | 3,174 | D | |
| Common StockF12 | Jun 24, 2026 | S | 837 | $315.705 | D | 2,337 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F13 | $44.25 | Jun 24, 2026 | M | 8,566 | D | — | Jun 5, 2034 | Common Stock | 8,566 | 0 | D |
| Stock Option (Right to Buy)F14 | $147.30 | Jun 24, 2026 | M | 3,034 | D | — | May 23, 2032 | Common Stock | 3,034 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026.
- F10The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F11The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F12The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F13This option was fully vested as of June 5, 2025.
- F14This option was fully vested as of May 23, 2025.
- F2The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F3The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F4The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F5The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F6The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F7The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F8The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F9The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.